1. Home
  2. EVER vs JANX Comparison

EVER vs JANX Comparison

Compare EVER & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EverQuote Inc.

EVER

EverQuote Inc.

N/A

Current Price

$29.10

Market Cap

928.5M

Sector

Technology

ML Signal

N/A

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

N/A

Current Price

$10.13

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EVER
JANX
Founded
2008
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
928.5M
1.0B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
EVER
JANX
Price
$29.10
$10.13
Analyst Decision
Buy
Buy
Analyst Count
8
18
Target Price
$32.33
★ $33.14
AVG Volume (30 Days)
684.7K
★ 946.4K
Earning Date
11-02-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 198.86
N/A
EPS
★ 1.53
N/A
Revenue
★ $163,349,000.00
$10,000,000.00
Revenue This Year
$18.77
$174.21
Revenue Next Year
$11.02
N/A
P/E Ratio
$18.76
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$13.88
$10.16
52 Week High
$31.20
$35.34

Technical Indicators

Market Signals
Indicator
EVER
JANX
Relative Strength Index (RSI) 63.75 25.34
Support Level $22.38 N/A
Resistance Level $31.20 $14.47
Average True Range (ATR) 1.57 1.16
MACD -0.06 -0.48
Stochastic Oscillator 66.18 0.33

Price Performance

Historical Comparison
EVER
JANX

About EVER EverQuote Inc.

EverQuote Inc operates an online marketplace for insurance shopping, connecting consumers with insurance providers, including carriers and agents. Its marketplace is powered by proprietary data and technology platform that delivers high-intent, pre-validated consumer referrals aligned with insurers underwriting and profitability requirements. The platform provides transparency and campaign management tools, enabling providers to evaluate marketing spend performance and manage return on investment. Consumers can visit insurance provider websites, engage by phone, or submit data to receive quotes. Services are free for consumers, and the company derives revenue principally from consumer inquiries sold as referrals to insurance providers. It derives a majority of revenue from Direct channels.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: